Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Study evaluates surveillance intervals after Barrett's esophagus ablation

Cotton CC et al. Gastroenterology. 2018 Apr 12. doi: 10.1053/j.gastro.2018.04.011.

Key clinical point: Baseline histologic grade was the most important predictor of recurrence after radiofrequency ablation of Barrett’s esophagus.

Major finding: The proposed surveillance intervals were 1 year, followed by 3 years, followed by more than 5 years for patients with completely eradicated low-grade dysplasia. For cases of high-grade dysplasia or carcinoma in situ, the proposed surveillance intervals were 3 months, 6 months, 1 year, and then annually.

Study details: An analysis of data from the United States Radiofrequency Ablation Registry and the United Kingdom National Halo Registry.

Disclosures: The National Institutes of Health and Barrx/Covidien/Medtronic provided funding. Dr. Cotton reported having no relevant disclosures. Three coinvestigators disclosed ties to Pentax Europe, Medtronic, Beamline Diagnostics, C2 Therapeutics, Boston Scientific, and CDx Medical.

Read the article.

Citation:

Cotton CC et al. Gastroenterology. 2018 Apr 12. doi: 10.1053/j.gastro.2018.04.011.

This Week's Must Reads

Vanderbilt staging best for predicting overall survival in retroperitoneal sarcoma, Huggett B & Cates J. Modern Pathology; 5 Nov. 2018. https://www.nature.com/articles/s41379-018-0166-8

Older patients with ccRCC may respond better to treatment than younger patients, Feulner et al. Urol Oncol. 2018 Nov 23. doi: 10.1016/j.urolonc.2018.11.006.

Still no validated biomarkers to select RCC treatment, D’Avella C et al. Urol Oncol. 2018 Nov 23. doi: 10.1016/j.urolonc.2018.10.027

DSS of ccRCC patients lower with high hTERT, Zanjani LS et al. Pathology. 2018 Nov 19. doi: 10.1016/j.pathol.2018.08.019.

ccRCC with papillary features best classified as a rare morphologic variant of ccRCC, Alaghehbandan R et al. Ann Diagn Pathol. 2018 Nov 22. doi: 10.1016/j.anndiagpath.2018.11.004.

Must Reads in Gastroenterology

Refractory esophagogastric cancer: Nivolumab plus ipilimumab ups response rate , Janjigian YY et al. J Clin Oncol. 2018 Aug 15. doi: 10.1200/JCO.2017.76.6212.

Study evaluates surveillance intervals after Barrett's esophagus ablation, Cotton CC et al. Gastroenterology. 2018 Apr 12. doi: 10.1053/j.gastro.2018.04.011.

Software boosts accuracy of colonoscopies, Tripathi PV et al. DDW 2018 (Digestive Disease Week, 2018). Presentation 133.

Colorectal cancer costs twice as much in US as Canada, Yezefski et al. ASCO 2018 Abstract LBA3579.

Fiber Intake and Survival After CRC Diagnosis, JAMA Oncol; ePub 2017 Nov 2; Song, Wu, et al